Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael Pellini
AddedMar 31, 2024
UpdatedMay 31, 2026
Michael Pellini

Michael Pellini

Board Member, Foundation Medicine

CrunchbaseLinkedIn

Michael Pellini's Career

Foundation Medicine
Foundation Medicine

Cambridge, MA, US

Board Member· Board
Tango Therapeutics
Tango Therapeutics

Boston, MA, US

Board Member· Board
Adaptive Biotechnologies
Adaptive Biotechnologies

Seattle, WA, US

Board Member· Board
TwinStrand Biosciences
TwinStrand Biosciences

Seattle, WA, US

Board Member· Board
Octave Bioscience
Octave Bioscience

Menlo Park, CA, US

Board Member· Board
Vineti
Vineti

San Francisco, CA, US

Board Member· Board
Thrive Earlier Detection
Thrive Earlier Detection

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael Pellini's Career

Foundation Medicine
Foundation Medicine
Public$96.5M6622010Cambridge, MA, US
Board Member· Board

Leadership at Foundation Medicine

Krishna YeshwantKrishna YeshwantBoard Member
Daniel O'DayDaniel O'DayBoard Member
Evan JonesEvan JonesBoard Member
Brian AlexanderBrian AlexanderCEO
Tango Therapeutics
Tango Therapeutics
Public$351M1102017Boston, MA, US
Board Member· Board

Leadership at Tango Therapeutics

Barbara WeberBarbara WeberBoard Member
José BaselgaJosé BaselgaCo-Founder
Timothy LuTimothy LuCo-Founder
Cary PfefferCary PfefferBoard Member
William G. KaelinWilliam G. KaelinBoard Member
Alexis BorisyAlexis BorisyBoard Member

Similar to Tango Therapeutics

Marengo TherapeuticsMarengo TherapeuticsCambridge, MA, USCancer Treatmentest. 2015Marengo TherapeuticsCambridge, MA, US · est. 2015

Marengo Therapeutics: A clinical-stage biotech company dedicated to improving patient lives.

Series B · $80M36
GO TherapeuticsGO TherapeuticsCambridge, MA, USCancer Therapiesest. 2014GO TherapeuticsCambridge, MA, US · est. 2014

GO Therapeutics, Inc.: A US-based biotech firm specializing in cancer-specific immunotherapies and drugs.

Series A · $5M11
TG TherapeuticsTG TherapeuticsNew York City, NY, USCancer Treatments, Pharmaceuticalsest. 1993TG TherapeuticsNew York City, NY, US · est. 1993

TG Therapeutics: A biopharmaceutical firm innovating cancer treatments, focusing on non-Hodgkins lymphoma.

Public · $205M226
Window TherapeuticsWindow TherapeuticsBoston, MA, USCancer Treatmentest. 2021Window TherapeuticsBoston, MA, US · est. 2021

Window Therapeutics: A biotech firm innovating targeted cancer treatments for unmet patient needs.

Angel · $256k4
Adaptive Biotechnologies
Adaptive Biotechnologies

Seattle, WA, US

Board Member· Board
TwinStrand Biosciences
TwinStrand Biosciences

Seattle, WA, US

Board Member· Board
Octave Bioscience
Octave Bioscience
Series A$91M922014Menlo Park, CA, US
Board Member· Board

Leadership at Octave Bioscience

Tom HawesTom HawesBoard Member
George ScangosGeorge ScangosBoard Member
Melinda ThomasMelinda ThomasCo-Founder
William HagstromWilliam HagstromBoard Member
Vineti
Vineti
Series C$115.3M3752016San Francisco, CA, US
Board Member· Board

Recent news

a16z-backed Rooms.xyz lets you build interactive, 3D rooms and simple games in your browserTechCrunch · 2023

Leadership at Vineti

Eli CasdinEli CasdinBoard Member
Stephen TingStephen TingCo-Founder
Emily MeltonEmily MeltonBoard Member
Amy DurossAmy DurossCo-Founder
Heidi HagenHeidi HagenCo-Founder
Nina KjellsonNina KjellsonBoard Member

Similar to Vineti

Vita TherapeuticsVita TherapeuticsBaltimore, MD, USCell Therapiesest. 2018Vita TherapeuticsBaltimore, MD, US · est. 2018

Vita Therapeutics: Pioneering life-transformative treatments through cell engineering.

Series B · $63M33
ViTToria BiotherapeuticsViTToria BiotherapeuticsPhiladelphia, PA, USCell Therapiesest. 2021ViTToria BiotherapeuticsPhiladelphia, PA, US · est. 2021

Vittoria Biotherapeutics pioneers in gene-edited T-cell therapies, enhancing efficacy and safety in cell-based treatments.

Series B · $25M34
VintaBioVintaBioPhiladelphia, PA, USViral Vectorsest. 2020VintaBioPhiladelphia, PA, US · est. 2020

VintaBio: Expert CDMO provider for viral vectors, advancing cell and gene therapy manufacturing.

Series D · $64M15
Endpoint HealthEndpoint HealthPalo Alto, CA, USTests, Therapeuticsest. 2018Endpoint HealthPalo Alto, CA, US · est. 2018

Endpoint Health: Personalized therapies for immune-driven illnesses, improving patient outcomes.

Series D · $64.2M
Thrive Earlier Detection
Thrive Earlier Detection
Late Stage Private$367M1752019Cambridge, MA, US
Board Member· Board

Leadership at Thrive Earlier Detection

Christoph LengauerChristoph LengauerCo-Founder
Steven J. KafkaSteven J. KafkaBoard Member
Neil ExterNeil ExterBoard Member
Isaac KindeIsaac KindeCo-Founder
Nickolas PapadopoulosNickolas PapadopoulosCo-Founder
Kenneth KinzlerKenneth KinzlerCo-Founder

Similar to Thrive Earlier Detection

Early DetectionEarly DetectionSan Diego, CA, USCancerscreeningest. 2017Early DetectionSan Diego, CA, US · est. 2017

Early Detection, founded in 2017, develops non-invasive, accurate cancer screening tests in San Diego.

Seed · $282k7
GRAILGRAILMenlo Park, CA, USCancer Detectionest. 2016GRAILMenlo Park, CA, US · est. 2016

GRAIL, Inc., a Menlo Park-based biotech firm, specializes in early cancer detection using science and technology.

Public · $2B823
FreenomeFreenomeSouth San Francisco, CA, USCancer Detectionest. 2014FreenomeSouth San Francisco, CA, US · est. 2014

Freenome, a US-based company, is dedicated to providing tools for cancer detection, treatment, and prevention.

Late Stage Private · $1.1B375
Harbinger HealthHarbinger HealthCambridge, MA, USBlood Testsest. 2018Harbinger HealthCambridge, MA, US · est. 2018

Harbinger Health: Pioneering early blood cancer detection through innovative testing.

Series B · $190M77

Michael Pellini's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Michael Pellini

Steve PaulSteve PaulBoard Member · Voyager TherapeuticsMichael GreeleyMichael GreeleyCo-Founder · Flare Capital PartnersMike MortimerMike MortimerCo-Founder · GHO CapitalEric NeumannEric NeumannFounder · PanGenXRob WillsRob WillsBoard Member · CymaBay TherapeuticsMichelle GriffinMichelle GriffinBoard Member · Adaptive Biotechnologies